GLP-2 is a peptide hormone produced by proglucagon, which is associated with glycometabolism and lipid metabolism. GLP-2 is significantly related to type 2 diabetes and intestinal diseases such as short bowel syndrome (SBS) and inflammatory bowel disease (IBD), possibly as a biomarker for these diseases. Creative BioMart Biomarker offers sensitive testing service for GLP-2, ensuring providing accurate and reliable test results.
Introduction
GLP-2 is a 33-amino acid peptide hormone that is normally secreted by intestinal endocrine L cells but also expressed in the central nervous system (CNS). The L cell line is a special subgroup in the intestinal endocrine system, mainly distributed in the distal ileum and the entire colon. GLP-2, like GLP-1, is produced by proglucagon cleavage under the action of enzymes, and then released by L cells. The release of GLP-2 in the intestine is a hormonal response to the undigested nutrients present in the terminal ileum. The secretion and release of GLP-2 is a related response to dietary intake, especially for undigested nutrients such as long-chain free fatty acids and carbohydrates. The endocrine system of the digestive tract is a unique system with multiple effect mechanisms. The main function of this system is to optimize the efficiency of nutrient absorption. GLP-2 is a key component of this system and can help regulate the function of the intestinal mucosa. GLP-2 is a gastrointestinal hormone with multiple effect mechanisms. It can stimulate intestinal growth through the participation of secondary mediators and Akt phosphorylation. GLP-2 has the functions of increasing the length of the crypt-villus axis of the intestinal mucosa, inhibiting intestinal cell apoptosis and improving the adaptive response after bowel resection. In addition to the above physiological functions, GLP-2 can increase the blood flow of mesenteric vessels, reduce gastrointestinal motility, reduce mucosal damage caused by inflammation, and improve intestinal function by improving barrier function and Paneth cell-mediated immune protection. GLP-2 is also involved in the regulation of glycometabolism and lipid metabolism. Due to the multiple effect mechanisms of GLP-2 in the regulation of intestinal function, it has been used in the research of a variety of intestinal diseases, such as SBS, IBD, and enteritis caused by chemotherapy.
Figure 1. GLP-2 release by enteral nutrients and signaling effects (Sigalet, 2018)
Application of GLP-2 Detection
Plasma and serum GLP-2 levels can be studied as a biomarker in researches related to SBS, IBD, etc.
Our Advantages
- Guarantee high accuracy and sensitivity for GLP-2 detection
- Ensure high repeatability of GLP-2 detection
- Short turn-around time of detection service
- Competitive price in the market of GLP-2 detection services
- Multiple technology platforms for GLP-2 test services (ELISA, CLIA, etc.)
- Accept a wide range of sample types (plasma, serum, tissue homogenates, etc.)
Workflow of GLP-2 Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the GLP-2 detection procedure to ensure accurately quantify the level of GLP-2 in each sample.
At Creative BioMart Biomarker, we offer GLP-2 detection service which include several technical methods, you can communicate with our experts according to your research needs, and we will determine the final detection technical scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.
References:
- Orhan, A.; et al. The intestinotrophic effects of glucagon-like peptide-2 (GLP-2) in relation to intestinal neoplasia. The Journal of Clinical Endocrinology & Metabolism. 2018, 103(8): 2827-2837.
- Sigalet, D.L. Advances in glucagon like peptide-2 therapy. physiology, current indications and future directions. Seminars in Pediatric Surgery. 2018, 27(4): 237-241.
- Brubaker, P.L. Glucagon-like peptide-2 and the regulation of intestinal growth and function. Comprehensive Physiology. 2018, 8(3): 1185-1210.
- Amato, A.; et al. GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity. Journal of Endocrinology. 2016, 229(2): R57-66.
